| SYMPOSIUM ON INFECTIOUS AGENTS IN A MULTIDRUG RESISTANT GLOBE |
|
| Year : 2010 | Volume
: 2
| Issue : 3 | Page : 258-262 |
|
|
Quinolone and cephalosporin resistance in enteric fever
Malini Rajinder Capoor, Deepthi Nair
Department of Microbiology, Vardhman Mahaveer Medical College and Safdarjung Hospital, New Delhi, India
Correspondence Address:
Malini Rajinder Capoor
Department of Microbiology, Vardhman Mahaveer Medical College and Safdarjung Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-777X.68529
|
|
|
Enteric fever is a major public health problem in developing countries. Ciprofloxacin resistance has now become a norm in the Indian subcontinent. Novel molecular substitutions may become frequent in future owing to selective pressures exerted by the irrational use of ciprofloxacin in human and veterinary therapeutics, in a population endemic with nalidixic acid-resistant strains. The therapeutics of ciprofloxacin-resistant enteric fever narrows down to third- and fourth-generation cephalosporins, azithromycin, tigecycline and penems. The first-line antimicrobials ampicillin, chloramphenicol and co-trimoxazole need to be rolled back. Antimicrobial surveillance coupled with molecular analysis of fluoroquinolone resistance is warranted for reconfirming novel and established molecular patterns for therapeutic reappraisal and for novel-drug targets. This review explores the antimicrobial resistance and its molecular mechanisms, as well as novel drugs in the therapy of enteric fever. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
